SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRentokil Initial Regulatory News (RTO)

Share Price Information for Rentokil Initial (RTO)

Share Price is delayed by 15 minutes
Get Live Data
453.60    3.80 (0.84%)
Bid:
452.90
Ask:
453.20
Spread: 0.30 (0.066%)
Market Cap: £11.41b
RTO Live PriceLast checked at - London Stock Exchange

Intraday Rentokil Initial Share Chart

Q3 Trading Update

21 Oct 2021 07:00

RNS Number : 7297P
Rentokil Initial PLC
21 October 2021
 

  

 

21 October 2021

RENTOKIL INITIAL PLC (RTO) - THIRD QUARTER TRADING UPDATE

Strong momentum across our core businesses in Q3, continued good execution of M&A

 

 

(£m)

Q3 2021

Growth

AER

AER

CER

Ongoing Revenue1

761.3

0.9%

4.8%

Revenue

761.9

0.5%

4.4%

Excluding Disinfection

Ongoing Revenue1

750.2

10.2%

14.5%

Revenue

750.8

9.7%

14.0%

 

Overview of Q3 performance (at CER)

Q3 saw continued strong momentum in our core businesses with Group Ongoing Revenue, excluding disinfection services, growing by 14.5%, of which 6.7% was Organic2 and 7.8% was from acquisitions.

Pest Control delivered an excellent performance overall during the period. Despite our Australian, New Zealand, Malaysian and Indonesian operations being materially impacted by lockdowns in Q3, the category grew Ongoing Revenues by 18.3%, of which 7.5% was Organic. Ongoing Revenue in our Growth and Emerging markets grew by 18.7% and 15.6% respectively. In our North America business, a higher number of colleagues either off work with COVID-19 or self-isolating contributed to some labour shortages in the quarter. Despite this, our Pest Control business in North America continued to demonstrate very strong momentum, growing revenues by 24.6%, 10.1% Organic.

Our Core Hygiene business, excluding disinfection, delivered a 6.4% increase in Ongoing Revenue (4.7% Organic), reflecting good performances in the UK, Europe and Latin America but held back, as with Pest Control, by significant challenges associated with lockdowns and movement restrictions in Australia, New Zealand, Indonesia and Malaysia.

Sales from disinfection services have tapered in line with our expectations at £11.4m (Q1: £75.7m, Q2: £22.6m), a decline of £62.1m on this time last year. We are maintaining our guidance for disinfection revenues in H2 to be within the range of £10m to £20m.

Ongoing Revenue in our Protect & Enhance category grew by 6.2% (5.5% Organic), reflecting further recovery in our France Workwear, Ambius, UK Property Care and Dental Hygiene services businesses.

New category structure - Hygiene & Wellbeing

At our Capital Markets Day on 28 September, we announced that in response to the increasing importance of hygiene and wellbeing services, we are expanding our Hygiene category with effect from 1 January 2022. The enlarged category, called Hygiene & Wellbeing, will comprise our current Hygiene operations together with our Ambius, Dental Hygiene and Cleanroom services operations, previously part of our Protect & Enhance category. Adopting the new category structure in Q3 would give organic growth in Hygiene & Wellbeing of 6.6%.

M&A

​We completed nine acquisitions in Q3: seven in Pest Control; one in Hygiene; and the previously announced transaction with Boecker, which completed on 3 August and which offers both Pest Control and Hygiene services. As a result, we have acquired businesses with operations in Australia, Chile, Colombia, Guadeloupe, Lebanon, Saudi Arabia, United Arab Emirates and the US, as well as interests in affiliated businesses in Kuwait, Qatar and Nigeria. Together, these have combined annualised revenues in the year prior to acquisition of c.£48m. Q2's excellent momentum has been maintained in Q3 and also into Q4, and our anticipated full year expenditure on M&A remains in the region of at least £450m to £500m, as previously guided.

Commenting on today's announcement Andy Ransom, Chief Executive, said:

"We have delivered a strong performance from our core businesses in the quarter and are confident of sustaining this momentum for the remainder of the year. Assuming no further significant deterioration in trading conditions arising from the pandemic, our performance in Q3 - combined with further progress in our value-creating M&A programme - means we remain on track to deliver a full year performance in line with the guidance given at our interim results in July."

Enquiries:

 

Investors / Analysts:

Katharine Rycroft

Rentokil Initial plc

07811 270734

Media:

Malcolm Padley

Rentokil Initial plc

07788 978199

1Ongoing Revenue represents the performance of the continuing operations of the Group (including acquisitions) after removing the effect of disposed or closed businesses.

 

2Organic Revenue represents the growth in Ongoing Revenue excluding the effect of businesses acquired during the year. Acquired businesses are included in organic measures in the year following acquisition, and the comparative period is adjusted to include an estimated full year performance for growth calculations.

 

AER - actual exchange rates; CER - constant 2020 exchange rates

 

This announcement contains statements that are, or may be, forward-looking regarding the Group's financial position and results, business strategy, plans and objectives. Such statements involve risk and uncertainty because they relate to future events and circumstances and there are accordingly a number of factors which might cause actual results and performance to differ materially from those expressed or implied by such statements. Forward-looking statements speak only as of the date they are made and no representation or warranty, whether expressed or implied, is given in relation to them, including as to their completeness or accuracy or the basis on which they were prepared. Other than in accordance with the Company's legal or regulatory obligations (including under the Listing Rules and the Disclosure Guidance and Transparency Rules), the Company does not undertake any obligation to update or revise publicly any forward-looking statement, whether as a result of new information, future events or otherwise. Information contained in this announcement relating to the Company or its share price, or the yield on its shares, should not be relied upon as an indicator of future performance. Nothing in this announcement should be construed as a profit forecast.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTPPGUAUUPGGQU
Date   Source Headline
30th Jan 20074:48 pmRNSHolding(s) in Company
25th Jan 200711:52 amRNSAnnual Calendar 2007
15th Jan 20073:00 pmRNSMerger Update
11th Jan 20075:10 pmRNSAcquisition
11th Jan 20071:36 pmRNSHolding(s) in Company
2nd Jan 20078:47 amRNSAcquisition
22nd Dec 20069:23 amRNSAcquisition
21st Dec 20061:01 pmRNSDirector/PDMR Shareholding
20th Dec 20061:18 pmRNSTotal Voting Rights
20th Dec 200611:08 amRNSDirector/PDMR Shareholding
18th Dec 20067:09 amRNSAcquisition
11th Dec 200611:30 amRNSHolding(s) in Company
7th Dec 200610:44 amRNSDirector/PDMR Shareholding
30th Nov 20067:04 amRNSReview Electronic Security
30th Nov 20067:01 amRNSAcquisition
24th Nov 20062:37 pmRNSHolding(s) in Company
24th Nov 20062:36 pmRNSHolding(s) in Company
10th Nov 200612:34 pmRNSClarification - Q3 Update
9th Nov 20065:07 pmRNSHolding(s) in Company
9th Nov 20069:57 amRNSInvestor Day
8th Nov 20067:01 amRNS3rd Quarter Results
3rd Nov 20068:00 amRNSFrance - Regulatory Inquiry
30th Oct 20065:45 pmRNSHolding(s) in Company
25th Oct 20063:34 pmRNSAcquisition
18th Oct 20065:15 pmRNSHolding(s) in Company
10th Oct 20062:33 pmRNSBank Facilities
25th Sep 20063:20 pmRNSReporting Timetable
24th Aug 20067:00 amRNSInterim Results
11th Aug 20062:39 pmRNSHolding(s) in Company
21st Jul 20069:12 amRNSDisposal
14th Jul 20062:34 pmRNSDirector Declaration
5th Jul 200611:37 amRNSAnnual Information Update
3rd Jul 20064:45 pmRNSHolding(s) in Company
30th Jun 20067:03 amRNSAcquisition
12th Jun 20065:12 pmRNSHolding(s) in Company
12th Jun 20068:09 amRNSDisposal
5th Jun 20065:03 pmRNSHolding(s) in Company
1st Jun 20064:59 pmRNSDirector/PDMR Shareholding
22nd May 20065:20 pmRNSHolding(s) in Company
22nd May 20065:18 pmRNSHolding(s) in Company
17th May 20064:40 pmRNSDirectorate Change
16th May 20062:43 pmRNSHolding(s) in Company
4th May 20067:01 amRNSTrading Statement
6th Apr 200610:42 amRNSDirector/PDMR Shareholding
6th Apr 200610:42 amRNSDirector/PDMR Shareholding
31st Mar 200612:36 pmRNSEMTN Programme
10th Mar 20062:14 pmRNSDisposal
10th Mar 20061:23 pmRNSHolding(s) in Company
8th Mar 200612:45 pmRNSPublication of Prospectus
7th Mar 20061:46 pmRNSDisposal

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.